Information, support and friendship
AMEND is run by patients, for patients, to inform and support anyone affected by Multiple Endocrine Neoplasia (MEN) types 1, 2 and 3 and associated endocrine syndromes and tumours.
We are here to break the isolation so often felt by those with these rare diseases, and we would be delighted to welcome you into our 'family'.
The aim of our website is to direct you as quickly as possible to our support services and to information you can trust on MEN1, MEN2, MEN3, MTC (medullary thyroid cancer), FMTC (familial medullary thyroid cancer), adrenal gland tumours (phaeochromocytomas), parathyroid hyperplasia, paragangliomas, FIPA (familial isolated pituitary adenoma) and SDHx (succinate dehydrogenase) disorders.
MEN1 Breast Cancer Link
Dutch research just published in the New England Journal of Medicine has found that women with MEN1 have a higher risk of developing breast cancer, and at an earlier age, than those without the genetic mutation.
Lead researcher and endocrinologist, Dr Gerlof Valk from UMC in Utrecht said the findings support discussions regarding regular breast screening in women with MEN1.
UMC Utrecht Cancer Center oncologist, Professor Dr Elsken van der Wall stated: "It is important that women with the MEN1 syndrome now know that they have to be aware that they run the risk of developing breast cancer, because early treatment is always better."
UK Roadshow Meeting Visiting Expert
Dr John Ayuk will be the visiting expert at AMEND's UK Roadshow meeting on Saturday 13th September in central Birmingham.
Dr Ayuk is a Consultant Endocrinologist and Honorary Senior Lecturer at the University Hospital Birmingham, with special interests in pituitary and neuroendocrine tumours and MEN.
AMEND Roadshows are small informal afternoon meetings with free light lunch and refreshments, and provide a great opportunity to meet the team, explore AMEND resources, and get those burning questions answered.
Page 1 of 15